Release Date
March 24, 2003
Termination Date
March 24, 2004
Estimated time to complete this newsletter:
15 minutes
Estimated time to complete the entire series:
3 hours
Partial Posttest
and Evaluation
after each case
Click here to download newsletters
in Acrobat PDF format
Order print copies
This independent
CME activity is
supported by an
educational grant
from
GlaxoSmithKline.
|
Welcome to this 12-part case-based series. Case Studies in Recurrent Gynecologic and Lung Cancer: Chemotherapeutic Innovation addresses various dilemmas and options in treating non–small-cell lung cancer and ovarian cancer.
Learn about the most recent clinical trial results, innovative sequencing strategies, and the latest thinking on unique combination therapies.
Our distinguished faculty of oncologists is pleased to share its practical experience in applying these innovations to direct patient care.
Dear Colleague:
Ovarian cancer, the fifth leading cause of cancer death among women, poses a number of treatment challenges for oncologists. Because of an absence of symptoms in the early stages of ovarian cancer, most women present with advanced disease. Despite relatively high response rates among newly diagnosed patients to a combination of surgery and platinum-containing chemotherapy, ovarian cancer inevitably recurs. In the course of relapse, most patients develop platinum resistance, requiring treatment with second-line therapies, such as topotecan, docetaxel, gemcitabine, and etoposide. These evolving treatment strategies have shown promise in extending survival in patients with recurrent ovarian cancer. Evidence suggests that alternative dosing regimens with these agents can reduce the myelosuppression associated with them without compromising efficacy.
We are pleased to offer you the first of a 12-part series of CME newsletters, Case Studies in Recurrent Gynecologic and Lung Cancer: Chemotherapeutic Innovations. These case-based newsletters, designated for .25 CME credit each, will comprise gynecologic cancers and non–small-cell lung cancer. Presentations of patient cases and discussion of relevant treatment dilemmas and options by a distinguished faculty of oncologists are designed to update you on the latest clinical trial results and their implications for clinical practice.
This newsletter, the first in a series of eight on gynecologic cancers, presents the case of a 52-year-old restaurant manager, who, after initial treatment of stage III ovarian cancer with combination chemotherapy, experiences disease recurrence within 5 months. This case examines the appropriate choice for initial treatment, and for recurrent disease, as well as the appropriate dose and schedule for second-line therapy. The discussion of this case emphasizes practical strategies for determining effective dosing sequencing, in light of recent clinical trial data.
We hope you find this series helpful and informative, and that the discussions assist you in incorporating this information into your clinical practice.
Sincerely,
Eric Rowinsky, MD
Chair
Director, Clinical Research
Institute for Drug Development
Cancer Therapy and Research Center
Clinical Professor of Medicine
University of Texas Health Sciences Center
San Antonio, Texas |
|
 |
|
Faculty
Robert T. Morris, MD
Assistant Professor
Division of Gynecologic Oncology
Wayne State University School of Medicine
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan |
|
 |
Howard D. Homesley, MD
Clinical Professor
Vanderbilt University School of Medicine
Nashville, Tennessee |
|
 |
Jacqueline A. Evans, DO
Gynecological Oncologist
Lancaster General Hospital
Lancaster, Pennsylvania |
|
 |
Jonathan S. Berek, MD, MMSc
Professor and Chair, College of Applied Anatomy
Executive Vice Chair, Department of
Obstetrics & Gynecology
Chief of Gynecology and Division of
Gynecologic Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California |
|
 |
Larry E. Puls, MD
Director of Research, Gynecologic
Oncology Research & Development, PA
Clinical Associate Professor
Department of Obstetrics and Gynecology
University of South Carolina
Greenville, South Carolina |
|
 |
James P. Stevenson, MD
Associate Professor of Medicine
Abramson Cancer Center of the
University of Pennsylvania
Philadelphia, Pennsylvania |
|
 |
Michael B. Dabrow, DO
Associate Professor of Medicine
Chief, Division of Medical Oncology
University of Medicine and Dentistry of New Jersey–
School of Osteopathic Medicine
Stratford, New Jersey |
|
 |
Shou-Ching Tang, MD, PhD, FACP, FRCPC
Associate Director, Clinical Research
University of Miami Sylvester Comprehensive Cancer Center
Director of Solid Tumor Oncology
Division of Hematology and Oncology
Associate Professor of Medicine
University of Miami
Miami, Florida |
|
 |
Ronald D. Alvarez, MD
Professor, Department of OB/GYN
Division of Gynecologic Oncology
University of Alabama at Birmingham
Birmingham, Alabama |
|
 |
John R. Eckardt, MD
Director, Clinical Research
The Center for Cancer Care and Research
St. Louis, Missouri |
|
 |
top
Learning Objectives
This activity is designed for oncologists and oncologic healthcare professionals who treat patients with gynecologic or lung cancer. After completing this activity, the participant should be able to:
- Compare the efficacy and safety of available regimens for treating recurrent gynecologic and lung cancers.
- Consider the risks and benefits of extending the platinum-free interval and its impact on future responses to additional treatment regimens.
- Formulate a treatment strategy that maximizes outcomes and reduces toxicity through judicious sequencing of therapies and dosing schedules when treating patients with platinum-sensitive, recurrent gynecologic or lung cancer.
- Discuss future clinical applications, including activity and toxicity profiles, of novel combinations and schedules of chemotherapies, including topoisomerase inhibitors, alone or in combination with platinum agents, in the treatment of gynecologic and lung cancer.
top
CME Information
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This 12-part newsletter is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.
Projects In Knowledge designates this educational activity for a maximum of 3 Category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
To receive documentation of your participation in this 12-part CME activity, complete the newsletter posttest with a passing score of 70% or higher. Full instructions for submission are included on the posttest accompanying each CME newsletter. After passing each posttest, you will be issued a CME certificate of .25 credit.
top
Disclosure
The Disclosure Policy of Projects In Knowledge requires that the faculty participating in a CME activity disclose to the audience any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation, as well as any relationship with the funder of this activity.
Robert T. Morris, MD, has received grant/research support from GlaxoSmithKline.
Eric K. Rowinsky, MD, has received grant/research support from and is a consultant for GlaxoSmithKline.
The opinions expressed during this 12-part activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge or the funder.
This activity may include a discussion of therapies that are unapproved for use or investigational, ongoing research, or preliminary data. This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the prerogative of the physician caring for the patient.
This independent CME activity is supported by an educational grant from GlaxoSmithKline.
top
|